Merck Stock Slumps on $11.3 Billion Acquisition Concerns

Merck KGaA's stock price has dropped due to investors' concerns about its $11.3 billion acquisition of Bio-Techne, a deal that adds to worries about heavy spending and potential integration costs.

The recent loss of U.S. patent protection for Mavenclad, a multiple sclerosis drug, is another factor contributing to the decline in Merck's stock price.

Despite these challenges, Definium Therapeutics remains optimistic due to its lead drug DT120's strong late-stage trial results and special FDA status, which suggest regulators see promise in treating major depressive and anxiety disorders.

However, as a pre-revenue biotech with mounting losses and faster cash burn, Definium must continue to fund development without any product sales, which could lead to the need for more equity capital and potential dilution of existing shareholders.